



Corporate

Ind-Swift Limited

781, Industrial Area, Phase-II,
Chandigarh - 160 002 INDIA
Ph. : 0172- 4680800, 2638781
Fax : 0172-2652242
E-mail : corporate@indswift.com
CIN No. : L24230CH1986PLC006897

Ref.:ISL:CH:2022:

Date: 3rd June, 2022

The President,
Corporate Relationship Department,
Bombay Stock Exchange Limited,
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 524652

NSE Symbol: INDSWFTLTD

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Reg: Press Release of Product Launch

Dear Sir,


Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of the latest press release on "Product launch in Qatar" is enclosed as **Annexure-I**.


This intimation is also made available on the website of the company at <http://www.indswiftltd.com>.

The above is for your information and records.

With Regards

For IND SWIFT LIMITED


GINNY UPPAL
COMPANY SECRETARY



IND-SWIFT LIMITED LAUNCHES ITS PRODUCTS IN QATAR

Expanding its reach in the markets of GCC Countries , Ind-Swift Limited (ISL) launched its finished dosages products in the markets of Qatar.

At a recently held event, Indian Ambassador to Qatar Dr Deepak Mittal launched a range of cardio diabetic & antibiotic products of ISL in Qatar. The launch event was held in partnership with WellcareGroup .Wellcare Group is the authorized distributor of Ind-Swift's products in Qatar & is one of the leading healthcare distribution companies in Qatar and represents more than 100 brands with a distribution lineup of customers from leading government and semi-government establishments, private hospital and medical centres, pharmacies and other institutions.

The event was graced by IBPC President Jaffer Siddique, Normal Wong-Lead Instructor, University of Doha for Science & Technology, Dr Ashraf Karara-HOD at Doha Clinic Hospitals & Dr Anoj George-Vice President Indian Doctor's Club. Mr Sridhar, DGM-Middle East Region highlighted,during the event, the strict quality control & procedures followed at Ind Swift's MHRA approved facility from where the products to Qatar market shall be supplied. Mr. Sahil Munjal -Director operations expressed that the Company's focus to expand its products reach in the market of GCC Countries.

Current Status &Future plan in GCC Countries-

In UAE, currently, Ind-Swift has a total of 6 products (including line extensions) which are marketed by a dedicated team of 4 MRs and a National Sales Manager. Ind-Swift has major expansion plans to increase the product line to 23 products for UAE market.

With 27 products (including line extensions) under registration in Oman with our partner Al-Hasar Pharmacy, Oman is an important market amongst the GCC.

With current 8 products and tie up with its distributor-Wellcare group, Qatar is emerging as a potential focus market for Ind-Swift.

Apart from these countries, Ind-Swift is also supplying its products in market of Iraq & Yemen and making available quality products at an affordable price to customers.



About Ind-Swift Limited (Global Business Unit)

Established in 1986, Ind-Swift is a research driven pharmaceutical group known for world class finished dosage forms, active pharmaceutical ingredients, and intermediates. The group sees itself as a stakeholder in the service to humanity, offering quality pharmaceuticals that mitigate illness and suffering, and contribute to a healthier and better world.

Ind Swift Limited-Global Business Unit (ISL-GBU) was commissioned in 2006, to cater exclusively to the demand of the international markets for finished dosage forms. Products from GBU are now available in many countries of EU, Australia, Canada, Central & Latin America, Asia, Russia & CIS and Africa-including South Africa.

ISL-GBU is approved by MHRA, TGA, Health Canada, WHO-GMP & other leading regulatory agencies for tablets, hard gelatin capsules and dry powder-sachet. ISL-GBU is one of the few facilities that can provide specific environmental conditions for highly sensitive products.

GBU focuses to have significant presence in both the developed markets (European Union, Australia, Canada, Brazil, South Africa) & semi regulated markets (Africa, South East Asia, Latin America, & the CIS countries).

For the developing markets, ISL-GBU has a dedicated approach of developing products and out licensing to customers through flexible and customer oriented strategic alliances either through partnership, dossier rights or other strategic alliances for exploring various avenues of collaboration.

Ind-Swift has successfully launched its own branded generics in multiple countries like-Tanzania, Kenya, Ethiopia, French West Africa, Uganda & UAE with expansion plans in other GCC countries.

Today Ind-Swift has over 400 Marketing Authorizations and more than 300 under registration dossiers spread across Africa, South East Asia, Central & Latin America, GCC & CIS region. All activities are carried out by professionally qualified team members with expertise in respective fields.